Things are going well for the Ghent design and consultancy firm Maat-ontwerpers. The firm got off to a flying start. And in 2017, partner Peter Vanden Abeele was appointed city architect for Ghent. A turning point. Which direction did they want to take the company in? How could they become more professional? To face these challenges, Filip Buyse and Esther Jacobs decided that two of them would follow the SME Challenge programmeat Vlerick. The changes they are going through are now giving them renewed energy.
General Manager, Isaline Desclée, joined the Vlerick Executive MBA to consolidate her understanding of areas like finance. What she’s discovering is that the learning experience goes way beyond the financial statement.
Until last year, Jorge Pancorvo’s professional experience was entirely in consulting. But when he became Head of Marketing at MPSA – an NGO that harvests water from the air to boost the Peruvian water supply – he realised his future lay in the energy sector.
Johan Van Meenen was initially sceptical about enrolling on a management programme at Vlerick. Not because he’d already learnt everything there was to know, but because previous courses had taught him too little. Nevertheless he enrolled at Vlerick for the SME Excellence programme. But could this programme fullfil his expectations?
Dominique Van Den Putte is the owner of the chocolatier and confectioner, Duva Cerisettes & Chocolates. The company produces high-quality chocolate specialities for a niche market. In the past few years, the firm has put considerable effort into process optimisation, leading to rapid growth. This proved to be a turning point. The head of the company now felt that a more strategic perspective was needed, which is why she signed up for Vlerick’s SME Excellence Programme.
Developing a medicine to treat a life-threatening disease and bringing it to the market remains the ultimate dream for many scientists. This story became reality for the medicine caplacizumab. Bio-engineer Dr. Tinneke Denayer and her team played a crucial role in this achievement. They developed the caplacizumab medicine to treat patients with the life-threatening blood-clotting disorder aTTP (acquired thrombotic thrombocytopenic purpura). This medicine was recently also launched on its first market. To further support her practical experience with the relevant theoretical knowledge, Tinneke took the Executive Development Programme at Vlerick Business School. She finished the programme at the end of last year.